Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer
The side effects from taking futibatinib were manageable and similar in people with different types of cancer. To fully understand the safety of futibatinib, researchers will need to look at what side effects are reported in people taking futibatinib over a longer time in the real-world setting (outside of clinical trials).
Authors
- Nanae Hangai (ORCID: https://orcid.org/0009-0002-9190-4920)
- Volker Wacheck (ORCID: https://orcid.org/0000-0003-3962-5932)
- Junji Furuse (ORCID: https://orcid.org/0000-0003-0663-6117)
- Lipika Goyal (ORCID: https://orcid.org/0000-0002-9777-6221)
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- Bailey Anderson (ORCID: https://orcid.org/0000-0002-5907-9409)
- John A. Bridgewater (ORCID: https://orcid.org/0000-0001-9186-1604)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- Cancer Institute (WIA) (IN)
- Institut Gustave Roussy (FR)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
- Kanagawa Prefectural Hospital Organization (JP)
- Massachusetts General Hospital (US)
- London Cancer (GB)
- Integrated Oncology (United States) (US)
- Taiho Oncology (United States) (US)
- Kanagawa Cancer Center
- University College London (GB)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1080/14796694.2024.2414593
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00